These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2292533)

  • 1. In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.
    Holt HA; Bywater MJ; Reeves DS
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():7-12. PubMed ID: 2292533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
    Sheppard M; King A; Phillips I
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):573-81. PubMed ID: 1915400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.
    Rolston KV; Messer M; Nguyen H; Ho D; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):581-5. PubMed ID: 1915401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Infection; 1991; 19(5):363-9. PubMed ID: 1800378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
    Jones RN; Zurenko GE
    Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
    Reynolds R; Potz N; Colman M; Williams A; Livermore D; MacGowan A;
    J Antimicrob Chemother; 2004 Jun; 53(6):1018-32. PubMed ID: 15128723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
    Matsuzaki K; Yoshimori K; Shikano M; Watabe E; Sato Y; Hasegawa M; Kobayashi I; Yamanaka N
    Jpn J Antibiot; 2003 Jun; 56(3):171-9. PubMed ID: 12942788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.
    Wiedemann B; Jansen A
    J Antimicrob Chemother; 1990 Jul; 26(1):71-9. PubMed ID: 2211449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.